Northwest & Ethical Investments L.P. Lowers Stock Position in IQVIA Holdings Inc. $IQV

Key Points

• Northwest & Ethical Investments L.P. reduced its stake in IQVIA Holdings Inc. by 10.4%, holding 12,836 shares worth approximately $2.26 million as of the end of the first quarter.
• IQVIA recently reported earnings of $2.81 per share, exceeding estimates and showing a 5.3% increase in revenue year-over-year, with a total revenue of $4.02 billion for the quarter.
• Analyst ratings remain positive with the stock having a consensus rating of "Moderate Buy" and an average price target of $228.62, indicating strong potential for growth.

Northwest & Ethical Investments L.P. lowered its holdings in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 10.4% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 12,836 shares of the medical research company's stock after selling 1,483 shares during the quarter. Northwest & Ethical Investments L.P.'s holdings in IQVIA were worth $2,263,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. JPMorgan Chase & Co. grew its position in shares of IQVIA by 45.7% in the 1st quarter. JPMorgan Chase & Co. now owns 2,545,014 shares of the medical research company's stock worth $448,686,000 after buying an additional 798,534 shares during the last quarter. Northern Trust Corp boosted its stake in IQVIA by 16.2% in the fourth quarter. Northern Trust Corp now owns 1,791,229 shares of the medical research company's stock valued at $351,994,000 after acquiring an additional 250,141 shares in the last quarter. American Century Companies Inc. grew its holdings in IQVIA by 26.8% in the first quarter. American Century Companies Inc. now owns 1,438,995 shares of the medical research company's stock worth $253,695,000 after purchasing an additional 304,258 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of IQVIA by 2.9% during the first quarter. Dimensional Fund Advisors LP now owns 1,428,561 shares of the medical research company's stock worth $251,852,000 after purchasing an additional 40,699 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of IQVIA by 13.6% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,393,140 shares of the medical research company's stock valued at $273,766,000 after purchasing an additional 167,057 shares during the last quarter. Institutional investors own 89.62% of the company's stock.

Insiders Place Their Bets

In other news, insider Eric Sherbet sold 5,800 shares of the stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total value of $1,102,290.00. Following the sale, the insider owned 27,178 shares in the company, valued at $5,165,178.90. This represents a 17.59% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Keriann Cherofsky sold 549 shares of the stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total transaction of $105,149.97. Following the completion of the sale, the insider owned 2,910 shares in the company, valued at $557,352.30. The trade was a 15.87% decrease in their position. The disclosure for this sale can be found here. 1.60% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on IQV shares. Redburn Partners set a $188.00 target price on IQVIA in a research note on Friday, May 23rd. Evercore ISI boosted their price target on IQVIA from $170.00 to $180.00 and gave the stock an "outperform" rating in a research note on Wednesday, July 9th. Truist Financial upped their price objective on shares of IQVIA from $209.00 to $235.00 and gave the company a "buy" rating in a report on Wednesday, July 23rd. Barclays lifted their target price on shares of IQVIA from $165.00 to $185.00 and gave the stock an "equal weight" rating in a research note on Wednesday, July 23rd. Finally, JPMorgan Chase & Co. lowered their target price on shares of IQVIA from $232.00 to $177.00 and set an "overweight" rating for the company in a research note on Monday, May 19th. Seventeen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $228.62.

IQVIA Stock Performance

Shares of IQV stock traded up $5.5970 during trading hours on Friday, hitting $190.9870. The company's stock had a trading volume of 1,619,418 shares, compared to its average volume of 1,415,297. The stock has a market cap of $32.47 billion, a PE ratio of 27.64, a price-to-earnings-growth ratio of 2.10 and a beta of 1.30. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $252.88. The company has a 50 day moving average of $173.70 and a 200 day moving average of $167.96. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.45.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, topping analysts' consensus estimates of $2.77 by $0.04. The firm had revenue of $4.02 billion for the quarter, compared to analyst estimates of $3.96 billion. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The business's quarterly revenue was up 5.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.64 earnings per share. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. On average, sell-side analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.